Clario
Clario, a leading name in the digital health industry, is headquartered in the United States and operates extensively across Europe and Asia. Founded in 2020, the company has quickly established itself as a pioneer in patient-centric solutions, focusing on clinical trial support and data management services. Clario's core offerings include advanced eSource solutions, patient engagement tools, and comprehensive data analytics, all designed to enhance the efficiency and accuracy of clinical research. What sets Clario apart is its commitment to integrating technology with a deep understanding of patient needs, ensuring a seamless experience throughout the clinical trial process. With a strong market position, Clario has achieved significant milestones, including partnerships with major pharmaceutical companies and a growing portfolio of innovative products that streamline clinical operations.
DitchCarbon Score
How does Clario's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clario's score of 52 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Clario's reported carbon emissions
In 2023, Clario Holdings, Inc. reported total greenhouse gas emissions of approximately 54,229,000 kg CO2e, with emissions distributed across various scopes: 103,000 kg CO2e for Scope 1, 383,000 kg CO2e for Scope 2, and about 54,290,000 kg CO2e for Scope 3. The Scope 3 emissions are primarily driven by employee commuting, which accounts for approximately 40,063,000 kg CO2e, alongside significant contributions from purchased goods and services (about 3,395,000 kg CO2e) and capital goods (approximately 1,592,000 kg CO2e). Clario has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its entire value chain by 2045. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 63.6% and Scope 3 emissions by 25% by 2030, using 2021 as the baseline year. Long-term, Clario aims for a 90% reduction in absolute emissions across all scopes by 2045. These targets align with the Science Based Targets initiative (SBTi) and reflect Clario's commitment to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 103,000 | 000,000 | 000,000 |
| Scope 2 | 383,000 | 000,000 | 000,000 |
| Scope 3 | 40,063,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Clario is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
